MAXY continued to incur R&D costs through the JV with Astellas. The gene-shuffling technology was eventually sold to MAXY’s spin-off, CDXS for essentially nothing (#msg-56059056).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.